DUXAP9 and renal carcinoma: Meanwhile, we next evaluated that management of LY294002 in renal cancer cells also impaired the advancement of tumor cells growth of DUXAP9-overexpression cells through CCK-8 assays and colony formation assays (Figures 7F–H).